Abstract
For subglottic hemangiomas with suboptimal response to propranolol, transcatheter arterial sclerosing embolization (TASE) significantly reduces tumor size with minimal adverse effects. This intervention effectively improves airway stenosis in patients where oral propranolol has failed.
Introduction: The Challenge of Subglottic Hemangiomas
Infantile hemangiomas (IHs) are common benign tumors, but their occurrence in the subglottic region—the narrowest part of an infant's airway—presents a life-threatening emergency. Subglottic hemangiomas (SGH) account for only 1.5% of congenital airway anomalies but carry a mortality rate as high as 50% if untreated due to severe airway obstruction.
While oral propranolol is the standard first-line treatment, a subset of patients develops Propranolol-Resistant Infantile Hemangioma (PRIH). For these infants, traditional alternatives include long-term steroid use, laser ablation (which risks scarring), or invasive surgery and tracheostomy. This study evaluates TASE as a safer, minimally invasive second-line intervention for these resistant cases.
Methods: The TASE Procedure
The researchers conducted a retrospective analysis of 10 patients who failed to respond to at least four weeks of propranolol treatment. The TASE procedure involves a sophisticated interventional approach:
- Access and Mapping: Using a femoral artery approach, selective arteriography of the bilateral carotid and subclavian arteries is performed to pinpoint the specific "feeding" vessels of the tumor.
- Superselective Catheterization: A 2.1F microcatheter is used to reach the target vessels.
- Embolization: A combination of Pingyangmycin (a sclerosing antibiotic) and polyvinyl alcohol (PVA) particles (300–500 μm) is injected to physically block blood flow and chemically inhibit vascular endothelial cells.
The goal is to reduce blood flow velocity enough to trigger tumor involution while preserving surrounding healthy laryngeal tissue.
Results: Clinical Outcomes and Safety
The study reported a 100% technical success rate and a 100% overall response rate among the 10 infants (4 male, 6 female).
- Tumor Shrinkage: The median maximal diameter of the hemangiomas decreased significantly from 8.5 mm at baseline to 2 mm post-treatment ($P < .05$).
- Airway Improvement: All patients showed a reduction in laryngeal obstruction grades.
- Efficacy Grading: 60% of patients achieved an "excellent" result (76–100% reduction), 30% were "good" (51–75%), and 10% were "general" (26–50%).
- Safety Profile: No serious complications occurred. Minor adverse events, such as postoperative fever or mild cough, resolved within 48 hours.
Discussion: A Targeted Alternative to Invasive Surgery
The success of TASE relies on the ability to perform superselective embolization. SGHs often have complex blood supplies, drawing from the superior thyroid artery, brachiocephalic trunk, or facial artery. By addressing both the physical structure (via PVA) and the biological growth (via Pingyangmycin), TASE offers a "middle way" between failed drug therapy and radical surgery.
Crucially, TASE may prevent the need for tracheostomies. In infants, tracheostomies are associated with high mortality, speech delays, and significant caregiver burden. This minimally invasive approach allows for rapid airway recovery without the morbidity of open surgery.
Limitations and Future Directions
While promising, this study is limited by its small sample size (n=10) and retrospective design. Future research should involve multi-center prospective trials to compare TASE directly against other second-line therapies, such as Sirolimus, to establish a standardized treatment algorithm for propranolol-resistant subglottic hemangiomas.
Summary updated